Nanosys reaches settlement of patent infringement lawsuit against Nanoco Technologies

Nanosys, Inc. today announced it has agreed to settlement terms of a patent infringement lawsuit against Nanoco Technologies Ltd.

The lawsuit claimed that the United Kingdom firm's quantum dot technology infringes upon five seminal quantum dot patents held by Nanosys. In the settlement, Nanoco agreed to terminate its current U.S. business for its core-shell quantum dots. Those quantum dots were sold in the U.S. by its U.S. distributor, Sigma-Aldrich under the name Lumidots. In the settlement, Nanoco did not admit that the asserted patents are either infringed or valid. Additional terms of the settlement were not disclosed.

Nanosys is currently using its quantum dot technology to make process-ready components for solid state lighting, solar power and electronic display systems. Nanosys has the exclusive rights to more than 700 patents and applications covering fundamental aspects of its materials technology, including its quantum dot technology.

“Nanosys is committed to serving visionary manufacturers by creating process-ready components for industries including electronics, energy efficiency, and medical devices,” said Jason Hartlove, chief executive officer of Nanosys. “By enforcing ownership of our intellectually property, the manufacturers remain the real winners in having access to proven, trusted advanced material architecture, including quantum dot applications.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered MRI predicts outcomes in prostate cancer